tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Amgen price target raised to $342 from $328 at Piper Sandler

Piper Sandler raised the firm’s price target on Amgen (AMGN) to $342 from $328 and keeps an Overweight rating on the shares following quarterly results. With continued strong execution across the commercial portfolio, Amgen remains well-positioned to transcend its denosumab loss of exclusivity, the firm says. That dynamic coupled with continued pipeline advancement points to a strong case for multiple expansion from an EV/2026E EBITDA of about 13-times.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1